PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE
Author(s)
Swindle R1, Ye W2, Robinson RL1, Zhao Y11Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: To examine whether non-generic duloxetine and venlafaxine XR are essentially interchangeable in patients with major depressive disorder (MDD) or used selectively for patients with different treatment histories, costs, demographics, and comorbidities. METHODS: Using the US PharMetrics Database, we studied commercially insured individuals aged 18-64 initiating treatment with duloxetine or venlafaxine XR between July 2005 and July 2006, with ≥1 prior MDD diagnosis and continuous enrollment for 12 months prior to initiation date. Initiation was defined as the first use of either medication preceded by 3 months no prescription for or use of the same medication. Chi-square and logistic regression analysis of patients’ demographics, past-year medication use, and comorbidities were used to assess predictors of initiations with duloxetine versus venlafaxine XR. RESULTS: A total of 9641 patients (73.6% female) initiated treatment with duloxetine and 8514 (71.5% female) with venlafaxine XR. Compared to venlafaxine XR patients, duloxetine patients were older (45 vs. 42.4 years), had ≥3 unique prior pain medications (25.5% vs. 15.6%), SSRIs (59.5% vs. 52.7%), TCAs (12.6% vs. 7.8%), analgesics (63.1% vs. 51.3%), anticonvulsants (30.1% vs. 17.9%), hypnotics (30.2% vs. 22.3%), and had ≥8 unique comorbid medical conditions (38.6% vs. 29.1%) and pain diagnoses (76.3% vs. 67.8%) (all p-values <0.005). Logistic regression results revealed that 61% of duloxetine initiators and 61% of venlafaxine XR initiators were predictable from prior patient and treatment factors. The prior 6-month total health care costs were $1731 higher for future duloxetine patients than for future venlafaxine XR patients, and despite higher subsequent pharmacy costs, total health care costs declined for both medications after treatment with each drug began. CONCLUSIONS: MDD patients treated with duloxetine tended to have a more complex and costly antecedent clinical presentation compared with venlafaxine XR-treated patients, suggesting physicians do not use the two medications interchangeably and both may have unique roles on formularies.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
PMH75
Topic
Health Service Delivery & Process of Care, Study Approaches
Topic Subcategory
Post Marketing Studies, Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Mental Health